IbisVision
Newhouse
About IbisVision
Ibis Vision has developed ‘Ring of Sight’ (ROS), a unique eye test that is specifically designed for the early detection of glaucoma. Worldwide, glaucoma is the second most common cause of blindness and is caused by a build-up of pressure within the eye which in turn can damage the optic nerve and the nerve fibres from the retina. Once damage is detected, it is usually permanent and therefore it is vital to make the diagnosis as soon as possible to commence treatment. The ROS product is based on patented technology covering the use of visual field testing using a cursor and LED screen: the product is currently configured for use within a Windows environment and has two developed tests in play; the Full Threshold Test and the Suprathreshold Test. The ROS application will be hosted remotely and deployed via the latest in Cloud technology enabling users to access the application from wherever they are situated. All data is stored on secure encrypted servers to ensure data privacy and security is maintained at all times.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $5.7M
- Last round: Series Unknown (May 2023)
- Website: ibisvision.co.uk
- Phone: +44 (0) 1698 539 616
Industries & Categories
Health Care, Life Science, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/ibisvision-71742 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.